Study of aztreonam-avibactam for drug-resistant infections
Part of Infections clinical trials.
This trial studies a combination antibiotic called aztreonam-avibactam for treating infections caused by hard-to-treat bacteria, especially those that produce certain enzymes (MBLs). It aims to see how well this medicine works in hospital patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be hospitalized with an infection that is suspected or confirmed to be caused by multidrug-resistant bacteria.
- The infection must be caused by bacteria that produce MBL enzymes (your doctor will test for this).
- You must be treated with the study drug, a combination of two antibiotics (aztreonam and avibactam).
- You cannot participate if you or your legal representative refuses participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is checking how well a combination of two antibiotics, aztreonam and avibactam, works in patients who have a specific type of drug-resistant bacterial infection in the belly or lungs. It aims to offer a new treatment option for infections that are hard to cure.
This trial compares two IV antibiotics (aztreonam and avibactam) against the best available treatment for serious gram-negative infections. It may help people who are hospitalized and need IV antibiotics, especially when the infection is caused by certain gram-negative bacteria.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This study tests a new antibiotic called aztreonam-avibactam (ATM-AVI) for treating serious bacterial infections in hospitalized babies under 9 months old. The goal is to see if it's safe and works well.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
This trial looks at how well two antibiotics, ceftazidime-avibactam and fosfomycin, work together to treat infections caused by highly resistant bacteria called CRE. It may help find the best way to use these medicines.
Hear when a new Critical Care trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.